Loading stock data…
$0.17-0.01 (-4.23%)
AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States.
AIM ImmunoTech Inc. in the Healthcare sector is trading at $0.17 with a market capitalization of $7M. Wall Street consensus targets $4.25 (2 analysts), implying a +2401.5% move over the next 12 months. The stock is currently near its 52-week low of $0.17, remaining 69.7% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | — | $22,000↑ | $21,000↓ | $26,000↑ | $25,000 |
| Gross Profit | — | $18,000↑ | -$19,000↑ | -$42,000↓ | $15,000 |
| Operating Income | — | -$2.23M↑ | -$2.95M↓ | -$2.45M↑ | -$2.65M |
| Net Income | — | -$3.02M↑ | -$4.17M↓ | -$3.28M↓ | -$2.79M |
AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampli...